Institutional Cluster

CPRX

CATALYST PHARMACEUTICALS, INC.
MIXED
Impact 5/10
Horizonweeks Processed1mo ago
Institutional cluster: 23 buyers, 22 sellers (mixed)
Actionable Insight ◆ Mixed

The mixed cluster with heavy passive accumulation but active-manager distribution suggests no clear catalyst consensus. Monitor for insider buying or a catalyst (e.g., pipeline update, FDA decision) to break the stalemate. The Soros new stake adds optionality but is offset by the near-exit of Susquehanna and Jane Street.

DirectionMixed
Confidencemedium
Horizonweeks

Executive Summary

CPRX saw a mixed institutional cluster in Q2 2026: 23 buyers added $226.9M in new positions (led by JPMorgan, American Century, and a new Soros stake), while 22 sellers reduced holdings by $89.4M (led by BofA, Susquehanna, and Jane Street). The net buying of ~$137.5M is notable, but the heavy selling by quant and asset-manager funds creates a split signal with no insider corroboration, suggesting the stock is in a tug-of-war between accumulating passive/quant funds and distributing active managers.

Key Financial Metrics

Direction
mixed
Buy Value
$409.6M
Sell Value
$89.4M
Net Flow
$137.5M

Institutional Positions

Net institutional flow: $137.5M

▲ Buyers (23)

InstitutionActionChangePosition ValueValue Δ
JPMorganDOUBLED+579%$99.9M$88.8M
American Century CompaniesADD+34.2%$174.6M$72.1M
Soros Fund ManagementNEW—$10.8M$10.8M
UBSADD+47.4%$45.7M$21.3M
Millennium ManagementADD+39.3%$33.6M$14.6M

▼ Sellers (22)

InstitutionActionChangePrev ValueValue Δ
BofATRIM-56.8%$75.2M-$34.0M
Susquehanna International GroupNEAR_EXIT-95.1%$21.1M-$19.8M
Jane Street GroupNEAR_EXIT-96.6%$13.5M-$12.9M
Citadel AdvisorsNEAR_EXIT-85.3%$14.4M-$11.7M
Point72 Asset ManagementTRIM-58.5%$10.5M-$5.0M

Key Facts

  • 23 institutional buyers added $226.9M in new CPRX positions in Q2 2026
  • 22 institutional sellers reduced holdings by $89.4M, net buying of ~$137.5M
  • JPMorgan doubled its stake (+579% shares) to $99.9M, the largest buyer
  • Soros Fund Management initiated a new $10.8M position
  • BofA trimmed 56.8% of its stake, selling $34.0M, the largest seller
  • No open-market insider buying in the window — institutions-only signal
  • Analyst consensus is 0% bullish (0 Buy, 6 Hold, 3 Sell/Strong Sell)

Financial Impact

Net institutional buying of ~$137.5M in Q2 2026, with 23 buyers adding $226.9M and 22 sellers reducing $89.4M

institutional ownershipfloat turnover

Risk Factors

  • No insider buying corroborates the institutional signal, weakening conviction
  • Heavy selling by quant funds (Citadel, Point72) and asset managers (Susquehanna, Jane Street) suggests thesis fatigue
  • Analyst consensus is bearish with 0% bullish ratings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-CPRX-2026-Q2
15 reports for CPRX
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+60▲ +25.72%Feb 25, 2026
Filters
Rows
Reports for CPRX — sortable, filterable
TypeNow
Aug 22, 2026
5w ago
Institutional Cluster
MIXED ★ 5/10
—awaiting T+5——
Jul 24, 2026
9w ago
15-12G
BEARISH ★ 9/10
$31.49 awaiting T+5awaiting T+5——
Jul 17, 2026
11w ago
EFFECT
BEARISH ★ 5/10
$31.49 $31.49· 0.00%▼ −0.59%—
Jul 15, 2026
11w ago
25-NSE
BEARISH ★ 9/10
$31.49 $31.49· 0.00%▼ −0.98%—
Jul 8, 2026
12w ago
8-K
BULLISH ★ 6/10
$31.47 $31.49▲ +0.06%▲ +0.20%—
Jun 30, 2026
13w ago
DEFA14A
NEUTRAL ★ 3/10
$31.44 $31.49▲ +0.16%▼ −0.10%—
Jun 30, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$31.44 $31.49▲ +0.16%▼ −0.10%—
May 28, 2026
18w ago
PREM14A
BULLISH ★ 8/10
$31.23 $31.28▲ +0.16%▲ +0.45%—
May 12, 2026
20w ago
DEFA14A
NEUTRAL ★ 3/10
$31.14 $31.23▲ +0.29%▲ +0.21%—
May 11, 2026
20w ago
Press Release
BEARISH ★ 8/10
$31.14 $31.23▼ −0.29%▼ −0.21%—
Showing 10 of 15

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 22, 2026